Craig-Hallum lowered the firm’s price target on MiMedx (MDXG) to $13 from $14 and keeps a Buy rating on the shares following quarterly results. The company reiterated its 2025 guidance for high-single digit revenue growth and over 20% EBITDA margins, despite the LCD delay, the firm notes. Q1 revenue and EBITDA were in-line to slightly ahead of expectations.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue